arrow
D

Dickon Hayne

University of Western Australia
H指数:28
被引数:4,886

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reply to Tonghu Liu’s Letter to the Editor re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.009

回复刘通华致编辑的信:卡介苗加丝裂霉素与单用卡介苗治疗卡介苗初治非肌层浸润性膀胱癌:一项随机III期试验(ANZUP 1301)。欧洲泌尿外科杂志。待发表。http://dx.doi.org/10.1016/j.eururo.2026.01.009

2026-05-280
PRE
Reply to Daoyuan Li’s Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.011

回复李道远的智慧之言re: 卡介苗加丝裂霉素与单用卡介苗治疗卡介苗幼稚非肌层浸润性膀胱癌: 一项随机3期试验 (ANZUP 1301)。Eur Urol.在新闻中。http://dx.doi.org/10.1016/j.eururo.2026.03.011

2026-05-220
PRE
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin–naïve Non–muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)

卡介苗联合丝裂霉素与单用卡介苗治疗卡介苗初治非肌层浸润性膀胱癌:一项随机III期试验(ANZUP 1301)

2026-02-020
OAAI
A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol

人工智能驱动的生物标志物的多中心实施试验,以告知接受前列腺放疗的男性雄激素剥夺治疗的共同决定: stute方案

2025-02-130
OAAI
Immediate Versus Delayed Exercise on Health-related Quality of Life in Patients Initiating Androgen Deprivation Therapy: Results from a Year-long Randomised Trial

与延迟运动相比,早期运动对开始接受雄激素剥夺治疗的患者的健康相关生活质量的影响:一项为期一年的随机试验结果

2024-10-010
OAAI
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
2024-06-012
PRE